Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000364250 | SCV000332386 | uncertain significance | not provided | 2015-06-24 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001044757 | SCV001208572 | pathogenic | Charcot-Marie-Tooth disease type 2 | 2024-01-07 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with leucine, which is neutral and non-polar, at codon 50 of the LMNA protein (p.Arg50Leu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with clinical features of autosomal dominant limb-girdle muscular dystrophy and/or dilated cardiomyopathy with conduction system defects (Invitae). ClinVar contains an entry for this variant (Variation ID: 281553). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LMNA protein function with a positive predictive value of 95%. This variant disrupts the p.Arg50 amino acid residue in LMNA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10939567, 11503164, 18551513, 31498906). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV000364250 | SCV003814737 | uncertain significance | not provided | 2023-01-27 | criteria provided, single submitter | clinical testing |